Authorized purpose: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.
Clinical role
Notification-only, parallel worklist-prioritization support with an external alert and no image highlighting; standard-of-care review remains required
Images and patients
CT/CTA · Brain/head vasculature, specifically the ICA, M1, and M2 segments
Key limitation
Keep in mind: Intended for patients aged 22 or older and excludes old infarcts or other diseases affecting brain vasculature, metal artifacts such as coils, and surgical signs. The triage output is informational only, not diagnostic, and does not replace review of the original CTA. Standalone validation covered 602 retrospective cases from four U.S. sites.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/head vasculature, specifically the ICA, M1, and M2 segments Input: Contrast-enhanced CT angiography images of the head from patients aged 22 or older suspected of stroke-related circulation occlusion; Siemens and other CT vendors are listed, with exclusions for old infarcts or other brain-vascular disease, metal artifacts, and surgical signs.
Who uses it?Intended users: Qualified clinicians including radiologists, neuroradiologists, and neurologists; the comparison table also lists clinical administrators
What does the software produce?Output: A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.
What is its most important limitation?Key limitation: Intended for patients aged 22 or older and excludes old infarcts or other diseases affecting brain vasculature, metal artifacts such as coils, and surgical signs. The triage output is informational only, not diagnostic, and does not replace review of the original CTA. Standalone validation covered 602 retrospective cases from four U.S. sites.
Clinical takeaway. Clinical role: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: standalone testing used 602 retrospective CT datasets from 602 patients at four U.S. sites, including 307 positive cases with ICA, M1, or M2 occlusions. Two U.S.-board-certified neuroradiologists established ground truth with third-reader adjudication for disagreement. Observed sensitivity was 90.6% and specificity 88.8%; all cases processed in under 110 seconds with a median of 42 seconds.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.
Contrast-enhanced CT angiography images of the head from patients aged 22 or older suspected of stroke-related circulation occlusion; Siemens and other CT vendors are listed, with exclusions for old infarcts or other brain-vascular disease, metal artifacts, and surgical signs.
A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.
Intended for patients aged 22 or older and excludes old infarcts or other diseases affecting brain vasculature, metal artifacts such as coils, and surgical signs. The triage output is informational only, not diagnostic, and does not replace review of the original CTA. Standalone validation covered 602 retrospective cases from four U.S. sites.
FDA packet: standalone testing used 602 retrospective CT datasets from 602 patients at four U.S. sites, including 307 positive cases with ICA, M1, or M2 occlusions. Two U.S.-board-certified neuroradiologists established ground truth with third-reader adjudication for disagreement. Observed sensitivity was 90.6% and specificity 88.8%; all cases processed in under 110 seconds with a median of 42 seconds.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: standalone testing used 602 retrospective CT datasets from 602 patients at four U.S. sites, including 307 positive cases with ICA, M1, or M2 occlusions. Two U.S.-board-certified neuroradiologists established ground truth with third-reader adjudication for disagreement. Observed sensitivity was 90.6% and specificity 88.8%; all cases processed in under 110 seconds with a median of 42 seconds.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
syngo.CT LVO Detection regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K243145
Samplen=602
Sites4
IndependenceIndependence not established
K243145
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K243145. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Contrast-enhanced CT angiography images of the head from patients aged 22 or older suspected of stroke-related circulation occlusion; Siemens and other CT vendors are listed, with exclusions for old infarcts or other brain-vascular disease, metal artifacts, and surgical signs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Deployment compatibility is described with the syngo.via platform; DICOM is an applicable software standard and results can be sent to an external notification device. The FDA packet does not establish exact local RIS/PACS interface versions.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes deployment compatibility of syngo.CT LVO Detection with the syngo.via platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Feature syngo.CT LVO Detection syngo.CT Brain Hemorrhage Comparison" … "Deployment Compatibility syngo.via platform syngo.via platform, Similar". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes deployment compatibility of syngo.CT LVO Detection with the syngo.via platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Feature syngo.CT LVO Detection syngo.CT Brain Hemorrhage Comparison" … "Deployment Compatibility syngo.via platform syngo.via platform, Similar". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Deployment compatibility is described with the syngo.via platform; DICOM is an applicable software standard and results can be sent to an external notification device. The FDA packet does not establish exact local RIS/PACS interface versions.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for syngo.CT LVO Detection; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K243145 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Parallel notification of suspected anterior-circulation large vessel occlusion on acute head CTA for specialist review; notification only, not diagnosis.
Modality
CT/CTA
Anatomy
Brain anterior circulation: internal carotid artery and M1 segment of the middle cerebral artery
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Authorized purpose: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device
Modality
CT/CTA
Anatomy
Lung and pulmonary arterial segments containing incidental pulmonary embolism; subsegmental arteries are out of scope
Authorized purpose: Assist hospital networks and trained radiologists with workflow triage by flagging and communicating suspected ICA or MCA-M1 large-vessel occlusion findings in head CTA images.
Modality
CT/CTA
Anatomy
Head/brain vasculature, specifically the intracranial ICA and MCA-M1 segments.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.